

**ADVANCES IN
TUMOUR
PREVENTION,
DETECTION AND
CHARACTERIZATION**

editor: C. Maltoni

**VOLUME 3
BIOLOGICAL
CHARACTERIZATION
OF HUMAN
TUMOURS**

editors

Walter Davis

Cesare Maltoni

Advances in tumour prevention,
detection and characterization

Editor: C. Maltoni

Vol. 3
*Biological
characterization of
human tumours*

Proceedings of the Sixth International
Symposium on the Biological Characterization
of Human Tumours

Copenhagen, May 13-16, 1975

Editor

Cesare Maltoni

Linguistic Editor: P.R.J. Burch



1976

Excerpta Medica Amsterdam-Oxford
American Elsevier Publishing Co. Inc. New York

© *Excerpta Medica* 1976

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without permission in writing from the publisher.

International Congress Series No. 375

ISBN Excerpta Medica 90 219 0306 7

ISBN American Elsevier 0 444 15199 0

Library of Congress Cataloging in Publication Data

International Symposium on the Biological Characterization of Human Tumours, 6th, Copenhagen, 1975.

Biological characterization of human tumours.

(Advances in tumour prevention, detection, and characterization ;v. 3) (International congress series ;no. 375)

Includes indexes.

1. Cancer--Congresses. 2. Cancer--Chemotherapy--Congresses. 3. Tumors--Congresses. I. Davis, Walter, Ph.D. II. Burch, Philip Robert James. III. Title. IV. Series. V. Series: International Congress series; no. 375. (DNIM: 1. Neoplasms--Congresses. W3EX89 no. 375 1975 / QZ200 16127 1975b)

RC261.A1158 1975 616.9'92 75-45152

ISBN 0-444-15199-0 (American Elsevier)

Publisher:

Excerpta Medica
305 Keizersgracht
Amsterdam
P.O. Box 1126

Sole Distributors for the USA and Canada:

American Elsevier Publishing Company, Inc.
52 Vanderbilt Avenue
New York, N.Y. 10017

Typeset by Fototekst bv, Naarden

Printed in The Netherlands by VGI, Rijswijk

Sixth International Symposium on the Biological Characterization of Human Tumours

Organised by

The Co-ordinating Committee for Human Tumour Investigations

with the support of

The Danish Cancer Society

The Norwegian Cancer Society

The Institute of Cancer Research - London

Lundbeck and Company - Copenhagen

The Co-ordinating Committee of Human Tumour Investigations

Austria	Professor Dr H. Wrba	Vienna
Belgium	Professor H.J. Tagnon	Brussels
Bulgaria	Dr Maria Boeva	Sofia
Czechoslovakia	Professor V. Thurzo	Bratislava
Denmark	Dr J. Clemmesen	Copenhagen (Chairman)
Eire	Professor R.A.Q. O'Meara († 1974)	Dublin
Finland	Dr N. Oker-Blom	Helsinki
France	Professor E. Wolff	Paris
Germany (FRG)	Professor C.G. Schmidt	Essen
Germany (GDR)	Dr S. Tanneberger	Berlin
Hungary	Professor J. Sugar	Budapest
Italy	Professor C. Maltoni	Bologna
Netherlands	Dr R.J.G. Willighagen	Leiden
Norway	Professor O.H. Iversen	Oslo (Vice-Chairman)
Portugal	Professor A.S. Tavares	Oporto
Romania	Professor E. Craciun	Bucharest
Spain	Professor A. Llombart	Valencia
Sweden	Dr B. Sylvén	Stockholm
United Kingdom	Dr K. Harrap	London
Yugoslavia	Professor Z. Maricic	Zagreb
<i>Honorary President:</i>	Professor L.A. Elson	
<i>Secretary:</i>	Dr Walter Davis	
	International Agency for Research on Cancer	
	150 cours Albert-Thomas	
	69008 Lyon, France	

Executive Committee

Dr J. Clemmesen
Professor O.H. Iversen
Professor C. Maltoni
Professor J. Sugar

Symposium Organising Committee

Dr J. Clemmesen
Mrs Inge Glesner
Dr Med. J. Kieler
Mr Hjalgrim Jensen

Introduction

There is a very strong current of opinion in all field of cancer research and in most countries, that considers that what is called cancer research should be aimed at bringing some benefit to the cancer patient in a foreseeable future — or better still, be aimed at preventing cancer.

The coordinating committee for human tumour investigations that organized this symposium — the Sixth in a biennial series — was formed in 1961 under the inspiration of Professor Franz Bergel, FRS, with the avowed aim of encouraging research workers to come closer to the problems of human cancer. One feature of the committee's work was to foster closer contacts and therefore deeper understanding between the clinician and laboratory scientist.

The present symposium followed that pattern and in the book are an important group of papers presenting biochemical guidelines for cancer chemotherapy. Scientists from laboratories in Europe and the United States describe attempts to achieve a more selective and therefore more effective therapy based on an exploitation of the biochemical parameters that, if only marginally, distinguish the cancer cell from the normal.

The chapter devoted to classical and modern techniques for characterizing tumours takes a critical look at histological classification in the light of more modern techniques of cell kinetics and biochemistry. The concept that a tumour may be characterized by its clinical behaviour is discussed.

A great deal has already been published on the carcinogenicity of vinyl chloride, but the chapter in the present volume presents the current situation in review for those who have not been involved in the problem. There is no doubt that occupational carcinogenesis is an important aspect of cancer prevention since the hazards are identifiable and the work situation is one that is susceptible to control.

At each symposium, one type of cancer is looked at in depth and in the present volume, it is malignant melanoma that is presented. Epidemiological studies clearly related incidence of malignant melanoma to the amount of skin exposed to sunlight. Histological classification is discussed particularly in relation to prognosis, and the possibilities of immunotherapy of this tumour were considered. The problems of surgery and application of hyperthermic treatment were also discussed.

Four papers deal with the role of hormones particularly in relation to cancer of the breast, cervix and endometrium.

Ten further papers deal with recent work on various clinical and experimental aspects.

The Editors

Contents

Introduction

ix

I. Biochemical guidelines in cancer chemotherapy

Molecular basis of malignancy. <i>G. Weber, N. Prajda and J.C. Williams</i>	3
The biochemical assessment of the malignant status in man: Aspects related to tRNA modification. <i>T.P. Waalkes and E. Borek.</i>	15
Biochemical contributions in clinical cancer chemotherapy. <i>M.H.N. Tattersall</i>	32
Towards selectivity: The use of established anti-tumour agents and the design of new ones. <i>J.A. Stock</i>	45
The present status of clinical cancer chemotherapy. <i>J.F. Smyth</i>	52
Biochemical basis of malignancy in man. <i>G. Weber, R.A. Malt, J. Glover, J.C. Williams, N. Prajda and C. Waggoner</i>	60
Schedule design in cancer therapy: Is there a cell kinetic basis? <i>P. Lelieveld and L.M. Van Putten</i>	73
Comparative studies of the actions of methotrexate in spontaneous canine lymphosarcoma and normal tissue of dogs. <i>J.A. Straw, P. Klubes, D. Szapary and W.T. Wynn</i>	76
Effects of alkylating antitumor agents on the chromatin and on the cell membrane of Ehrlich and Yoshida ascites tumor cells. <i>H. Grunicke, B. Puschendorf, G. Raydt, F. Hirsch, J. Schnierda, H. Wolf, U. Bauer and G. Kiefer</i>	84
The steroid molecule as a carrier of cytotoxic groups. <i>I. Könyves and J. Liljekvist</i>	98
The alkylating agent: Does a knowledge of its mode of action suggest leads for improving its therapeutic effectiveness? <i>K.R. Harrap, P.G. Riches, E.W. Gascoigne, S.M. Sellwood and C.C. Cashman</i>	106
Investigation of the mode of action of ϵ -N-trimethyl-lysine (TML). <i>B. Szende, I. Benedeczký, A. Jeney and K. Lapis</i>	122
A study of human tumours growing in nude mice. <i>C.O. Povlsen</i>	127
Ectopic hormones as markers of response to therapy in cancer. <i>E.D. Gilby, L.H. Rees and P.K. Bondy</i>	132
Isopycnic separation of tumour cell populations in the study of chemotherapeutic agents. <i>L. Holczinger and K. Szikla</i>	139
Histochemical demonstration of tetrahydrofolate dehydrogenase in normal and leukaemic human bone marrow. <i>G. Gerzeli, P. de Piceis Polver, E. Vigo and G. Marini</i>	144
Spontaneous transformation of stromal fibroblasts derived from human lung cancers. <i>B. Azzarone and D. Pedullà</i>	149

II. Comparison of classical and modern techniques for the characterization of tumours

Histological classification, histological grading and clinical staging. <i>H. Stalsberg</i>	159
Kinetic characterization of malignant tumours. <i>O.H. Iversen</i>	173
The clinical characterization of human tumours in relation to treatment and prognosis. <i>M.J. Peckham</i>	185

Tissue culture criteria for characterising human cancers. <i>E.J. Ambrose, D.M. Easty and M. Mareel</i>	193
The biochemical classification of tumours. <i>E.H. Cooper</i>	203

III. Carcinogenicity of vinyl chloride: Current results

Production and use of vinyl chloride: Impact of the link between vinyl chloride monomer and cancer. <i>G.F. Pregaglia</i>	209
Carcinogenicity of vinyl chloride: Current results. Experimental evidence. <i>C. Maltoni</i>	216
Vinyl chloride: Epidemiological studies and preventive measures. <i>R. Owen</i>	238
Mutagenicity and metabolism of vinyl chloride. <i>R. Montesano and H. Bartsch</i>	242

IV. Malignant melanomas

Epidemiology of malignant melanoma of the skin in Norway with special reference to the effect of solar radiation. <i>K. Magnus</i>	249
Histological classification of malignant melanoma in relation to prognosis and cytogenesis. <i>O.H. Iversen, T.E. Larsen, T.H. Grude and K. Magnus</i>	260
Histological and ultrastructural characterization and experimental chemotherapy of malignant melanoma. <i>J. Sugár, O. Csuka, S. Gábor, J. Tóth, S. Somfai-Relle, I. Pályi and Z. Szentirmay</i>	274
Immune reactions in patients with malignant melanoma, and possible causes of failure of control. <i>M.G. Lewis, G. Rowden and B. Burke</i>	283
Problems of surgical treatment of melanomas. <i>G. Olsen</i>	301
Hyperthermic regional perfusion of malignant melanoma. <i>G. Moricca, R. Cavaliere and A. Caputo</i>	304

V. Hormones and cancer

Influence of some hormone therapeutic substances on oestradiol receptor analysis in various organs. <i>E. Heise, M. Görlich and Ch. Kleitke</i>	313
Studies on progestogen receptors in breast cancer with a synthetic progestogen, DU-41165. <i>L. Terenius</i>	321
Comparative steroid investigations of sera and urine from patients with mastopathia and breast cancer. <i>I. Hindy, I. Számel and S. Eckhardt</i>	324
Some hormonal problems in patients with either endometrial or cervical cancer. <i>S. Madajewicz, J. Haruppa, J. Kamińska, E. Ploch, J. Rustowski and K. Czešnín</i>	326

VI. Clinical and experimental studies

Immunotherapy of human melanoma with autologous tumor specific antigens and/or BCG: Characterization of the antigens and immunological follow-up of the patients. <i>M. Micksche, C. Cerni, E.M. Kokoschka and H. Wrba</i>	337
Modulation of the immune response of cancer patients. <i>F. Barboni, C. Rovinetti, G. Nubile and P. Zulli</i>	346
The mode of action of alkaloids. <i>O. Csuka, J. Sugár and I. Sajo</i>	350
Cell membrane markers of T and B lymphocytes and monocytes in leukemias and hematiosarcomas. <i>D. Belpomme, D. Dantchev, R. Joseph, A. Santoro, N. Lelarge, F. Feuilhade de Chauvin, D. Grandjon and G. Mathé</i>	357

Characterization of malignancy through transplantation into young chick blastoderms. <i>M. Mareel, L. Vakaet and L. De Ridder</i>	367
Characterization of malignancy in organotypical culture. <i>L. De Ridder and M. Mareel</i>	370
Characteristics of primary and serially transplanted tumours and derived cultures. <i>B.F. Deys and G.W. Barendsen</i>	374
Factors related to tumour spread in the body. <i>W.A. Boggust</i>	383
Presence of fetal aldolase C in some intestinal tumors. <i>J. Banroques, M.S. Martin, A. Hatzfeld and F. Schapira</i>	391
Clinical significance of LDH isoenzymes on extracts from normal and malignant tissue of GI-tract. <i>S. Pérez-Cuadrado, P. Carda-Abella and J. Maté-Jimenez</i>	395
Index of authors	405
Subject index	407

Chapter I

*Biochemical guidelines in cancer
chemotherapy*

Molecular basis of malignancy*

George Weber, Noemi Prajda** and Jim C. Williams

*Laboratory for Experimental Oncology, Indiana University School of Medicine,
Indianapolis, Ind., U.S.A.*

The objectives

The purpose of this paper is to analyze the strategy of the cancer cell as it is expressed in the biochemical phenotype. When a normal cell is transformed to a cancer cell, two major biochemical events emerge. These alterations in gene expression relate to the neoplastic transformation itself and to the degrees in the expression of the malignant state.

The alterations in the genotype in neoplasia are expressed in the various biological aspects of the transformed cells, including growth rate, invasiveness and ability to metastasize, and also in the morphological, immunological and biochemical properties. We have been able to detect these alterations in the genotype by analyzing the biochemical phenotype through the application of the molecular correlation concept as an experimental and conceptual tool.

This paper concisely analyzes the approaches and results achieved by the molecular correlation concept and presents the integrated evidence for the presence and emergence of the enzymatic and metabolic imbalance as it is linked with (a) the neoplastic transformation, and (b) the degrees in the expression of malignancy.

Difficulties in the early studies of biochemistry and chemotherapy of neoplasia

During the 1940's and the early 1950's, the understanding of the biochemistry of the cancer cell progressed relatively little because of various drawbacks in the methodics and the conceptual approaches employed. The first problem was caused by the constant shifting from tumor to tumor, from human neoplasms to viral-induced avian tumors, from murine leukemias to rat solid tumors, etc., in the hope that one peculiar metabolic or enzymatic alteration, 'lesion' or 'deletion' would be found that would characterize 'the' cancer cell. A second major difficulty lay in the measurement of metabolic pathways or enzymes where frequently the guideline appeared to be chiefly the ease and feasibility of the assay. However, since some of the enzymes were assayed incorrectly and their function in intermediary metabolism was not understood, the investigations yielded little conceptual advance. As a result of the apparent lack of meaningful metabolic systems, the lack of emphasis on comparing the biochemistry of the neoplastic tissues with their homologous counterparts, and the failure to select enzymes whose function and significance were clearly established, some workers suggested that the biochemistry of cancer yielded only a picture of 'diversity' and random alterations that provided no rhyme, no reason, no pattern. Some of these misconceptions survive in the current literature.

* This work was supported by United States Public Health Service Grants CA-05034 and CA-13526.

** Permanent address: National Institute of Oncology, Budapest, Hungary.

Such problems in the metabolic studies on cancer had their counterpart in the apparent lack of progress in the chemotherapy of neoplastic diseases. The selective chemotherapy of tumors in man had a slow start, not because of lack of drugs or lack of well directed efforts, but because of the circumstances in which the anticancer drugs had to be tested. In those early trials, chemotherapy was mostly restricted to terminal cases. However, the condition of the patient and the enormous tumor burden provided little chance for the identification and establishment of clinically useful drugs. A detailed analysis of the successful overcoming of these and other difficulties by clinicians and scientists who achieved appropriate conditions for the testing of anticancer drugs in man has been reviewed elegantly (Frei, 1972; Zubrod, 1972). Important aspects of the breakthrough in clinical chemotherapy have been the learning of the pharmacology and toxicology of the anticancer drugs and the development of capabilities in dealing with the unavoidable bone marrow and other toxicities through biochemical rescue, the availability of sterile laminar flow rooms and various immunological techniques that have brought chemotherapeutic cures for ten neoplastic diseases in man.

Progress in understanding the molecular basis of malignancy: The molecular correlation concept

A major step towards recognition of the pattern of metabolic imbalance in neoplastic cells was achieved through a detailed analysis of a number of key enzymes and metabolic pathways in the very rapidly growing NK (Novikoff) hepatoma. The biochemical pattern was compared with suitable homologous control tissues such as liver of normal adult rats and developing and regenerating rat liver. By focussing the studies on these truly comparable systems, a definite biochemical pattern in the tumor was identified (Weber and Cantero, 1959). Subsequently, a new liver neoplasm, the 5123-D, which had a very slow growth rate and was histologically similar to normal liver, became available from H.P. Morris. In a comparative study of the slow-growing 5123-D hepatoma, the very rapidly growing NK hepatoma, and the normal liver, it was recognized (Weber, 1961) that there were a number of prerequisites which should permit elucidation of the biochemical basis of malignancy. In 1961, the essential aspects of the conceptual and experimental methods of the molecular correlation concept were introduced into the studies of the biochemistry and metabolic regulation of neoplastic cells (Weber, 1961).

The molecular correlation concept specified the need to analyze the neoplastic transformation and progression in (a) a meaningful biological model system by, (b) examining key enzymes and opposing and competing metabolic pathways and (c) comparing the results with those obtained in an array of appropriate control tissues (Weber, 1974a).

(a) Biological model system: Spectrum of hepatomas of different growth rates and malignancy

Whereas the 5123-D tumor in 1961 was very similar to normal liver, the very rapidly growing NK tumor appeared to be the example of the full-blown hepatic neoplastic transformation. In order to analyze the molecular correlates of neoplastic transformation and malignancy, there was need for a series of hepatomas that exhibited different biological malignancy, growth rates and histological degrees of differentiation. In our studies hepatomas were obtained chiefly from H.P. Morris and also from A.B. Novikoff and M.D. Reuber and others. This made it possible to set up a spectrum of liver tumors of different malignancy that provided a biological model system for the testing of the conceptual and experimental approaches of the molecular correlation concept.

(b) The concept of key enzymes

In this Laboratory biochemical work was undertaken only on enzymes and metabolic pathways the function of which was elucidated. A great deal of metabolic and regulatory studies were also

carried out to clarify the kinetics and regulatory behavior of these enzymes and pathways. As a consequence of such investigations, the concept of key enzymes was introduced in the investigations on metabolic regulation and neoplasia. Our studies revealed that metabolic regulation is exerted through control of a number of key enzymes, especially those that oppose each other in antagonistic pathways of synthesis and catabolism. By concentrating on determining the behavior of key enzymes in a spectrum of liver tumors of different growth rates, the pattern of imbalance was recognized in all metabolic pathways examined so far in this Laboratory (for reviews, see Weber, 1973b, 1974a,b).

(c) The need for appropriate control tissues

It was established that for the evaluation and interpretation of the biochemical pattern and its specificity to neoplasia, the biochemistry of a number of control systems had to be compared with that of liver tumors (Weber, 1974b). For this purpose, the liver of adult normal rats of the same strain, sex, age and weight as the tumor-bearing rats are used. It is inadvisable to use the liver of the tumor-bearing rat, the host liver, because it is subject to numerous hormonal and nutritional influences and these artifacts frequently and unpredictably invalidate a comparison between the biochemistry of the host liver and that of the tumor.

Among the valid, relevant control systems is the regenerating liver that is to be compared with the liver of the sham-operated controls. In the study of differentiation, the postnatal period from ages 5 or 6 days to adulthood is meaningful. It is an error to attempt to draw conclusions from assays on rat liver in embryo or during immediate postnatal development because the embryonic liver in the rat is a hemopoietic organ. Unless appropriate corrections are made for this fact, the results cannot be interpreted readily and the conclusions may be misleading.

Classifications achieved through application of the molecular correlation concept

Careful work carried out in this Laboratory and in other Centers has led us to recognize the following relationships in which the biochemical strategy of the cancer cell is expressed (Weber, 1974a).

(a) Malignancy-linked alterations: Class 1

These enzymatic and metabolic alterations are linked with the increase in tumor malignancy and growth rate in the model system. The key enzymes and metabolic pathways in this group are indicators of the degrees in the expression of the malignant properties in the different lines of cancer cells.

(b) Transformation-linked alterations: Class 2

There are certain enzymatic and metabolic alterations that occur in all hepatomas irrespective of growth rate and malignancy. Since the reprogramming of gene expression that is manifested in the emergence of these biochemical alterations appears even in the slowest growing, least malignant hepatomas, we assume that these metabolic alterations are linked with the neoplastic transformation per se.

(c) Coincidental alterations: Class 3

A number of biochemical changes occur in the hepatomas without any relationship to growth rate, malignancy or transformation. In contrast to the key enzymes that belong to Classes 1 and 2, the enzymes in Class 3 are present in an excess and they apparently do not become limiting to

the processes of intermediary metabolism. These latter enzymes are not rigorously controlled and their ups and downs represent the randomness and the diversity by which some research workers have allowed themselves to be misled to believe that there is no pattern in the biochemistry of the cancer cell.

Are the alterations in tumor cells ordered or random? With the experience the molecular correlation concept provides, it is clear that this is an erroneous question. The experimental results reveal that neoplastic cells have both ordered and random manifestations. It seems inadvisable to concentrate on the randomness and diversity because the job is to discover the underlying pattern that relates to the neoplastic transformation and the progressive expression of the degrees of the malignancy. The experimental evidence indicates that what is important for neoplasia is ordered; what is not, is the randomness and the diversity.

This conclusion draws attention to the fact that in the design of chemotherapy the drugs are to be directed against the key enzymes that show a linking with the degrees in the expression of malignancy or with the malignant transformation per se.

Analysis of the molecular basis of malignancy in cancer cells

The biochemical imbalance of the cancer cells has been examined in detail in this Laboratory for a number of metabolic areas and key enzymes. Table 1 provides a partial list of the areas investigated. In the following a brief summary of the imbalance will be given and an attempt will be made to pinpoint the selective advantages that this enzymatic and metabolic imbalance confers to the cancer cell.

Carbohydrate metabolism: Enzymatic and metabolic imbalance

Carbohydrate metabolism was the first testing ground of the molecular correlation concept and a series of original papers and reviews were devoted to this subject (Weber, 1961, 1974a,b). Table 2 gives the present view of the imbalance of carbohydrate metabolism in neoplastic liver.

This Table shows various aspects of the malignancy-linked metabolic imbalance that operates in the spectrum of hepatomas of different growth rates. These biochemical alterations confer selective advantages to the cancer cells.

TABLE 1 *Characterization of biochemical imbalance in the following metabolic areas*

Carbohydrate (gluconeogenesis, glycolysis)
Pentose phosphate (oxidative and non-oxidative pathways)
Pyrimidine (de novo and salvage pathways)
Purine (IMP synthesis, degradation and utilization)
Urea cycle
Ornithine utilization
Polyamine biosynthesis
Membrane cAMP synthesis and degradation
Protein and amino acid

Conclusions

An ordered pattern is revealed in

malignancy-linked (Class 1)
and transformation-linked (Class 2)
alterations of key enzymes and opposing pathways

TABLE 2 Carbohydrate metabolism: Phenotypic evidence for reprogramming of gene expression in neoplasia

Synthetic enzymes	Key gluconeogenic enzymes*	Decreased
Catabolic enzymes	Key glycolytic enzymes**	Increased
Metabolic imbalance	Ratios of key glycolytic/key gluconeogenic enzymes	Increased
Isozyme shift	High K_m isozymes* Low K_m isozymes**	Decreased Increased
Relation to malignancy	Alterations are co-variant with growth rate	Malignancy-linked imbalance
Biological role	(a) Imbalance in glycolytic/gluconeogenic enzymes leads to increase in glycolysis (b) Isozyme shift leads to decreased responsiveness to physiological controls	
		Confers selective advantages to cancer cells

* Glucose-6-phosphatase (G-6-Pase), fructose-1,6-diphosphatase (FDPase), phosphoenolpyruvate carboxykinase, pyruvate carboxylase. ** Hexokinase (HK), phosphofructokinase (PFK), pyruvate kinase. * Glucokinase, liver-type pyruvate kinase. ** HK, muscle-type pyruvate kinase.




FIG. 1 Integrated pattern of glycolysis, gluconeogenesis, pentose phosphate pathways, purine synthesis and degradation. The imbalance in hepatomas is indicated by the thick (increased activity) and dotted (decreased activity) arrows.

Pentose phosphate metabolism: Phenotypic evidence for reprogramming of gene expression in neoplasia

The various aspects of the reprogramming of gene expression in pentose phosphate metabolism may be briefly summarized. The main alterations are the increases in all hepatomas in the activities of the key enzymes, G-6-P dehydrogenase and transaldolase, that should provide an increased potential for pentose biosynthesis (Weber et al., 1974). The enzyme that is involved in the immediate utilization of ribose-5-phosphate, PRPP (phosphoribosylpyrophosphate) synthetase, is increased in the rapidly growing hepatomas. These observations indicate that both the production and the utilization of pentose phosphate may be increased in transformed cells (Fig. 1) and this alteration in gene expression should confer selective advantages to the cancer cells.

It is important that the increase in G-6-P dehydrogenase and transaldolase occurs in all hepatomas; thus, these alterations in gene expression are linked to the neoplastic transformation *per se*.

The increased capacity for production of ribose-5-phosphate and its enzymatic conversion to PRPP provides an increased potential for the biosynthesis of this precursor used both by the *de novo* and the salvage pathway of purine biosynthesis (Fig. 1).

Purine metabolism: Phenotypic evidence for reprogramming of gene expression in neoplasia

As summarized in Table 3, there is evidence for a marked imbalance in purine biosynthesis and degradation in the hepatoma spectrum. Glutamine PRPP amidotransferase, the first enzyme committed to *de novo* purine biosynthesis, is increased in all the hepatomas (Katunuma and Weber, 1974; Prajda et al., 1975). Thus, the increase is a transformation-linked alteration in gene expression. There is also evidence that the 5'-nucleotidase is decreased in these hepatomas. Current studies of Prajda and Weber (to be published) indicate that the rate-limiting enzyme of purine degradation, xanthine oxidase, is decreased in all hepatomas. It was also observed that

TABLE 3 *Purine metabolism: Phenotypic evidence for reprogramming of gene expression in neoplasia*

Synthetic enzymes	Key enzymes of IMP synthesis*	Increased
Degradative enzymes	Key enzymes of IMP catabolism**	Decreased
Enzymatic imbalance	Ratios of key synthetic/catabolic enzymes***	Increased
Metabolic imbalance	Ratios of pathways of synthesis of IMP/catabolism of IMP	Increased
Relation to malignancy	Ratio of imbalance is co-variant with growth rate	Malignancy-linked imbalance
	Amidotransferase increased in all hepatomas	Transformation-linked imbalance
Biological role	(a) Imbalance in anabolic/catabolic enzymes of IMP metabolism leads to increased <i>de novo</i> IMP biosynthesis (b) Imbalance provides increased synthetic potential and decreased loss of precursors for purine biosynthesis	Confer selective advantages to cancer cells

* PRPP synthetase, glutamine PRPP amidotransferase.

** 5'-Nucleotidase, xanthine oxidase.

*** Glutamine PRPP amidotransferase/xanthine oxidase.

TABLE 4 DNA metabolism: Phenotypic evidence for reprogramming of gene expression in neoplasia

Synthetic enzymes	Key enzymes of UMP*, TTP**, and DNA* synthesis	Increased
Degradative enzymes	Key enzymes of UMP and thymidine (TdR) catabolism**	Decreased
Enzymatic imbalance	Ratios of synthetic/catabolic enzymes	Increased
Metabolic imbalance	Ratios of TdR to DNA/TdR to CO ₂ pathways	Increased
Relation to malignancy	Alterations are co-variant with growth rate	Malignancy-linked imbalance
Biological role	(a) Imbalance in anabolic/catabolic enzymes of UMP metabolism leads to increased de novo DNA synthesis (b) Imbalance in anabolic/catabolic enzymes of TdR metabolism leads to increased salvage pathway to DNA synthesis	
		Confers selective advantages to cancer cells

* Aspartate transcarbamylase, dihydroorotase. ** Ribonucleotide reductase, dCMP deaminase, dTMP synthase, TdR kinase, dTMP kinase. * DNA polymerase. ** Dihydrouracil dehydrogenase (DH), dihydrothymine DH.




FIG. 2 Integrated pattern of de novo and salvage pathways of pyrimidine synthesis and degradation. The imbalance in the hepatomas is indicated by the thick and dotted arrows. The attacking points of some of the chemotherapeutic drugs used in man are shown for cytosine arabinoside (ARA-C), the anti-folates and hydroxyurea.